Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

CRISPR Therapeutics AG

Contributing Author

Recent Articles by CRISPR Therapeutics AG

Aug-03
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results CRSP CRSP +7.06% GlobeNewswire
May-28
CRISPR Therapeutics to Participate in Upcoming Investor Conferences CRSP +5.32% GlobeNewswire
May-06
CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference CRSP +5.15% GlobeNewswire
May-04
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results CRSP GlobeNewswire
Apr-07
CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference CRSP GlobeNewswire
Mar-11
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering CRSP -5.44% GlobeNewswire
Mar-10
CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering CRSP -10.17% GlobeNewswire
Feb-12
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results CRSP CRSP +8.46% GlobeNewswire
Jan-12
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones CRSP GlobeNewswire
Jan-05
CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference CRSP GlobeNewswire
Dec-22
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies CRSP GlobeNewswire
Nov-10
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results CRSP GlobeNewswire
Nov-08
CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering CRSP GlobeNewswire
Oct-10
CRISPR Therapeutics Presents New Preclinical Data for CTX460 Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Editing Platform CRSP GlobeNewswire
Oct-01
CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress CRSP GlobeNewswire
Sep-22
CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe CRSP GlobeNewswire
Sep-09
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025 CRSP GlobeNewswire
Sep-02
CRISPR Therapeutics to Participate in Upcoming Investor Conferences CRSP GlobeNewswire
Aug-04
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results CRSP +6.24% CRSP -6.71% GlobeNewswire
Jun-30
CRISPR Therapeutics Named to TIME's Most Influential Companies List of 2025 CRSP GlobeNewswire
Jun-26
CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline CRSP GlobeNewswire
May-29
CRISPR Therapeutics to Participate in Upcoming Investor Conferences CRSP GlobeNewswire
May-19
CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies CRSP GlobeNewswire
May-06
CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310 Targeting ANGPTL3 CRSP -11.86% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)